Company Overview and News

 
Diploma entities have a win on bonds

2017-10-10 businessnews.com.au
QBE Insurance Group has recorded one win and one loss this month as it battles in the Supreme Court for the financial scraps left after the collapse of Perth companies Capital Works Constructions and Diploma Group.
Upvote Downvote

 
Diploma maintains faith despite liquidation order

2017-05-23 businessnews.com.au
UPDATE: Diploma Group boss Nick Di Latte says the company will continue to push forward with its proposal to revive the company and provide a return to creditors, after provisional liquidators were appointed to 20 Diploma-related entities today.
Upvote Downvote

 
Diploma fails in revival bid

2017-05-23 businessnews.com.au
Diploma Group has failed in its last-ditch attempt to revive the collapsed development and construction group, with liquidators appointed to 20 related entities today.
Upvote Downvote

 
Diploma goes into liquidation

2017-05-23 businessnews.com.au
Liquidators have been appointed to Perth-based commercial construction and property development company Diploma Group, which collapsed last year owing creditors millions of dollars after 40 years in business.
Upvote Downvote

 
Morning Headlines

2017-05-22 businessnews.com.au
The Di Latte family are pushing ahead with their proposed rescue of Diploma Group despite yesterday’s appointment of provisional liquidators to the failed property developer. The West
Upvote Downvote

 
Mark my words podcast

2017-05-19 businessnews.com.au
In this Business News podcast Mark Pownall and Dan Wilkie discuss the Officeworks IPO, the WA economy, Diploma Group, and philanthropy and giving.
Upvote Downvote

 
Diploma holds off ASIC action

2017-05-12 businessnews.com.au
Diploma Group has been granted a two-week lifeline to finalise its plan to provide a return to creditors of the collapsed building and development firm.
Upvote Downvote

 
Diploma unable to start new jobs

2017-01-17 businessnews.com.au
The building regulator says conditions have been imposed on Diploma Group, limiting its ability to carry out work after the Belmont-based business fell into the hands of administrators just before Christmas.
Upvote Downvote

 
Gull NZ, Golden Grove deals cap off 2016

2017-01-03 businessnews.com.au
The last 10 days of 2016 were a busy period for WA corporate deals, with the Rae family attracting a bumper price for its Gull New Zealand business, Chinese group MMG selling the Golden Grove mine, Diploma Group going into receivership and seven new listings on the ASX.
Upvote Downvote

 
More hurdles on horizon for Diploma

2016-12-05 businessnews.com.au
An embattled Perth-based developer has capped off a turbulent 2016 by selling one of its most prominent projects.
Upvote Downvote

 
Company Update

2016-05-11 asx.com.au
Upvote Downvote

 
 
Appendix 4D

2016-02-22 asx.com.au
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...